<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02497391</url>
  </required_header>
  <id_info>
    <org_study_id>14629</org_study_id>
    <secondary_id>I1V-MC-EIBA</secondary_id>
    <nct_id>NCT02497391</nct_id>
  </id_info>
  <brief_title>A Study of Different Particle Sizes of Evacetrapib in Healthy Participants</brief_title>
  <official_title>A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Particle Sizes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if there is any difference in the way the body
      handles 3 types of evacetrapib tablets with different particle sizes. Information about any
      side effects will also be collected. This study will consist of 3 study periods. Participants
      will be dosed 3 times during the entire study. Each study period will consist of an inpatient
      stay for 3 days - the day before dosing (Day -1), dosing day (Day 1) and the day after dosing
      (Day 2). Then participants will be asked to return to the clinical research unit (CRU) daily
      for outpatient appointments up to Day 8. The overall length of this study is about 7 weeks
      from first dose to end of study. Screening will take place within 28 days prior to the first
      dose of evacetrapib and follow-up will take place 21 days after the last dose of evacetrapib.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Evacetrapib</measure>
    <time_frame>Baseline to 168 hours following administration of evacetrapib on Day 1 of each study period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration versus Time Curve from Zero to Infinity (AUC[0-âˆž]) of Evacetrapib</measure>
    <time_frame>Baseline to 168 hours following administration of evacetrapib on Day 1 of each study period</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Evacetrapib Reference (R)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of evacetrapib tablet given one time during one study period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evacetrapib Test 1 (T1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of evacetrapib tablet given one time during one study period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evacetrapib Test 2 (T2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of evacetrapib tablet given one time during one study period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evacetrapib</intervention_name>
    <description>administered orally</description>
    <arm_group_label>Evacetrapib Reference (R)</arm_group_label>
    <arm_group_label>Evacetrapib Test 1 (T1)</arm_group_label>
    <arm_group_label>Evacetrapib Test 2 (T2)</arm_group_label>
    <other_name>LY2484595</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overtly healthy participants of non-child bearing potential

          -  Have a body mass index of 18 to 32 kilograms per square meter (kg/m^2)

          -  Must be willing to make oneself available for the whole study and be willing to follow
             study procedures

        Exclusion Criteria:

          -  Have known allergies to evacetrapib, compounds or components related to this drug, or
             have a history of significant allergic reactions of another origin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Singapore</city>
        <zip>117597</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2015</study_first_submitted>
  <study_first_submitted_qc>July 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2015</study_first_posted>
  <last_update_submitted>December 15, 2015</last_update_submitted>
  <last_update_submitted_qc>December 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Evacetrapib</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 18, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

